Developments in Viral Vector-Based Vaccines

Vaccines

Takehiro Ura¹  Kenji Okuda¹ 

[1] id="af1-vaccines-02-00624">Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Jap

关键词: viral vector;    vaccine;    CTL;    MVA;    adenovirus;   

DOI  :  10.3390/vaccines2030624

来源: mdpi

【 摘 要 】

Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.